Hib Vaccine adds 225mcg to the toxic load of Aluminum in the first few months of life

Re-shared from Vi-Ta.Org Childhood Vaccine – Vaccine Injury-Teaching Alliance (vi-ta.org)

Hib Vaccine How Are They Made?

Infant immune systems do not respond well to sugars from the outer coat of bacteria. To improve the immune response, these sugars are purified and bound to a toxin (tetanus or diptheria) or protein (Neisseria). Some brands also add an aluminum adjuvant to further improve immune response.

Pros and Cons

Pros

• Able to prevent life-threatening bacterial meningitis and pneumonia.

Cons

• New strains of bacteria are evolving that are not covered by the vaccine. 

• Immunity is often short-lived.

• Fail to activate cellular immunity.

• Often contain aluminum, which is a known neurotoxin. 

• 
  

The Illness: Haemophilus Influenza is a bacterial infection that is transmitted through contact with infected person’s cough, mucus, or saliva. The bacteria usually remains in the nose, ears, or throat and causes minor cold symptoms.  Although infrequent, it can cause meningitis, blood infections, bone infections, and pneumonia. Severe cases of HiB are diagnosed through a blood test or spinal tap. The treatment for severe infection is intravenous antibiotics.

Cost/Benefit Analysis: Infant bacterial meningitis is a serious, life-threatening condition, but extremely rare at about 25 cases per year. Breastfed infants are at lower risk than bottle-fed infants. HiB vaccines have one of the best safety profiles of all vaccines. PedVaxHIB also contains 225 micrograms of aluminum and will add to the toxic load of aluminum during the first months of life, so parents concerned about this should consider the ACTHIB version that does not contain aluminum. Receipt of HIB vaccines is also correlated with increased incidence of developing Type 1 Diabetes. It is unclear if the correlation is specific to this vaccine or a result of adding yet one more vaccine to the schedule and therefor increasing the amount of immune activation children are being subjected to.

Other Considerations: It should also be considered that use of HiB vaccines, the incidence of meningitis caused by Haemophilus Influenzae A and other strains has increased. Due to the increased incidence of Haemophilus strains not normally circulating, adults with no prior immunity to these newer strains are contracting these infections at higher rates.

The Vaccines: HiB vaccines are made by isolating sugars from the membrane of the bacteria. Since these sugars alone are not enough to make the body mount a sufficient immune response, they are either bound to the very reactive tetanus toxoid or injected along with an aluminum adjuvant.

Age Given: 2 months, 4 months, 6 months, 15 months

Package Insert information can be found here. https://www.immunize.org/fda/#hib

Information concerning adverse events can be found in section 6, which contains information on the clinical trials as well as the post-marketing data.

Vaccine Ingredients: ActHIB:

• HIG sugar/ tetaus toxoid complex

• sugar water

• saline solution

Vaccine Ingredients: PedVaxHIB:

• HIB sugar/ Neisseria protein complex

• saline solution

• Aluminum 225 micrograms

HiB: Haemophilus Influenzae Type B

1. Bruce, Michael G et al. “Haemophilus influenzae serotype a invasive disease, Alaska, USA, 1983-2011.” Emerging infectious diseases vol. 19,6 (2013): 932-7. doi:10.3201/eid1906.121805 https://pubmed.ncbi.nlm.nih.gov/23735653/

2. Adam, H J et al. “Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination.” Vaccine vol. 28,24 (2010): 4073-8. doi:10.1016/j.vaccine.2010.03.075 https://pubmed.ncbi.nlm.nih.gov/20398617/

3. Sadeghi-Aval, Pouya et al. “Emergence of non-serotype b encapsulated Haemophilus influenzae as a cause of pediatric meningitis in northwestern Ontario.” The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale vol. 24,1 (2013): 13-6. doi:10.1155/2013/828730 https://pubmed.ncbi.nlm.nih.gov/24421786/

4. Rubach, Matthew P et al. “Increasing incidence of invasive Haemophilus influenzae disease in adults, Utah, USA.” Emerging infectious diseases vol. 17,9 (2011): 1645-50. doi:10.3201/eid1709.101991 https://pubmed.ncbi.nlm.nih.gov/21888789/

5. Resman, F et al. “Invasive disease caused by Haemophilus influenzae in Sweden 1997-2009; evidence of increasing incidence and clinical burden of non-type b strains.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 17,11 (2011): 1638-45. doi:10.1111/j.1469-0691.2010.03417.x https://pubmed.ncbi.nlm.nih.gov/21054663/

6. Classen, John Barthelow, and David C Classen. “Clustering of cases of insulin dependent diabetes (IDDM) occurring three years after hemophilus influenza B (HiB) immunization support causal relationship between immunization and IDDM.” Autoimmunity vol. 35,4 (2002): 247-53. doi:10.1080/08916930290028175 https://pubmed.ncbi.nlm.nih.gov/12482192/

7. Wahlberg, J et al. “Vaccinations may induce diabetes-related autoantibodies in one-year-old children.” Annals of the New York Academy of Sciences vol. 1005 (2003): 404-8. doi:10.1196/annals.1288.068 https://pubmed.ncbi.nlm.nih.gov/14679101/

8.  Classen, J B, and D C Classen. “Vaccines and the risk of insulin-dependent diabetes (IDDM): potential mechanism of action.” Medical hypotheses vol. 57,5 (2001): 532-8. doi:10.1054/mehy.2001.1352 https://pubmed.ncbi.nlm.nih.gov/11735306/

Pc: Pneumococcal Disease

1. Mehtälä, Juha et al. “Competition between Streptococcus pneumoniae strains: implications for vaccine-induced replacement in colonization and disease.” Epidemiology (Cambridge, Mass.) vol. 24,4 (2013): 522-9. doi:10.1097/EDE.0b013e318294be89 https://pubmed.ncbi.nlm.nih.gov/23676265/

2. Norton, Nancy B et al. “Routine pneumococcal vaccination of children provokes new patterns of serotypes causing invasive pneumococcal disease in adults and children.” The American journal of the medical sciences vol. 345,2 (2013): 112-20. doi:10.1097/MAJ.0b013e3182517785 https://pubmed.ncbi.nlm.nih.gov/22814362/

3. Huang, Susan S et al. “Continued impact of pneumococcal conjugate vaccine on carriage in young children.” Pediatrics vol. 124,1 (2009): e1-11. doi:10.1542/peds.2008-3099 https://pubmed.ncbi.nlm.nih.gov/19564254/

4. Dagan, Ron. “Serotype replacement in perspective.” Vaccine vol. 27 Suppl 3 (2009): C22-4. doi:10.1016/j.vaccine.2009.06.004 https://pubmed.ncbi.nlm.nih.gov/19545935/

Meningococcal Vaccine

1. Mehtälä, Juha et al. “Competition between Streptococcus pneumoniae strains: implications for vaccine-induced replacement in colonization and disease.” Epidemiology (Cambridge, Mass.) 24,4 (2013): 522-9. doi:10.1097/EDE.0b013e318294be89 https://pubmed.ncbi.nlm.nih.gov/23676265/

2. Norton, Nancy B et al. “Routine pneumococcal vaccination of children provokes new patterns of serotypes causing invasive pneumococcal disease in adults and children.” The American journal of the medical sciences 345,2 (2013): 112-20. doi:10.1097/MAJ.0b013e3182517785 https://pubmed.ncbi.nlm.nih.gov/22814362/

3. Huang, Susan S et al. “Continued impact of pneumococcal conjugate vaccine on carriage in young children.” Pediatrics 124,1 (2009): e1-11. doi:10.1542/peds.2008-3099 https://pubmed.ncbi.nlm.nih.gov/19564254/

4. Dagan, Ron. “Serotype replacement in perspective.” Vaccine 27 Suppl 3 (2009): C22-4. doi:10.1016/j.vaccine.2009.06.004 https://pubmed.ncbi.nlm.nih.gov/19545935/CDC Surveillance Data: https://www.cdc.gov/meningococcal/surveillance/surveillance-data.html

5. Shinefield, Henry R. “Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use.” Vaccine 28,27 (2010): 4335-9. doi:10.1016/j.vaccine.2010.04.072 https://pubmed.ncbi.nlm.nih.gov/20452430/

6. Wang, Ping et al. “CRM197-induced blood-brain barrier permeability increase is mediated by upregulation of caveolin-1 protein.” Journal of molecular neuroscience : MN 43,3 (2011): 485-92. doi:10.1007/s12031-010-9471-5 https://pubmed.ncbi.nlm.nih.gov/21080104/

7. Özerman Edis, Bilge et al. “Cross-reacting material 197 (CRM197) affects actin cytoskeleton of endothelial cells.” General physiology and biophysics 36,4 (2017): 383-389. doi:10.4149/gpb_2017006 https://pubmed.ncbi.nlm.nih.gov/28653650/

I am indebted to Dr. Robert Sears and Dr. Neil Miller for a substantial amount of the information concerning individual vaccines. For more information on each illness and vaccine, please see The Vaccine Book by Dr. Sears. For summaries of research studies concerning vaccines, please see Miller’s Review of Critical Vaccines Studies. Both books are indispensable references that belong on the bookshelf of every parent and vaccine safety advocate